EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 3.0

Eribulin plus Pyrotinib in Trastuzumab-Resistant, HER2-Positive Advanced Breast Cancer: A Single-Arm, Multicenter Phase II Trial (EPIC Trial)

Ruoyang Li, Meiqi Wang iD, Xiangshun Kong, Jie Ma, Xiuheng Qi, Zhenchuan Song iD

Drug Design, Development and Therapy · 2025

DOI: 10.2147/dddt.s547569 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Drug Design, Development and Therapy, 2025. Verfasst von Ruoyang Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Breast Center, Fourth Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China. Hauptthemen laut MEDLINE: Acrylamides, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Drug Resistance, Neoplasm. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcrylamidesAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsDrug Resistance, NeoplasmFuransKetonesErb-b2 Receptor Tyrosine KinasesTrastuzumabAdultAgedFemaleHumansMiddle AgedPolyether PolyketidesAminoquinolines

Stichwörter der Autor:innen

breast cancereribulinhuman epidermal growth factor receptor 2pyrotinibtrastuzumab-resistant

Substanzen

AcrylamidesFuransKetonesErb-b2 Receptor Tyrosine KinasesTrastuzumabPolyether PolyketidesAminoquinolinesERBB2 protein, humaneribulinpyrotinib

Autor:innen und Institutionen

  • Breast Center, Fourth Hospital of Hebei Medical University, Shijiazhuang, People's Republic of China.
  • Department of Breast Surgery, Xingtai People's Hospital, Xingtai, People's Republic of China.
  • Department of Breast Surgery, TangShan People's Hospital, Tangshan, People's Republic of China.
  • Department of Oncology, Hebei Petrochina Central Hospital, Langfang, People's Republic of China.

ORCID-Profile: Meiqi Wang, Zhenchuan Song

Zitieren

APA

Li, R., Wang, M., Kong, X., Ma, J., Qi, X., & Song, Z. (2025). Eribulin plus Pyrotinib in Trastuzumab-Resistant, HER2-Positive Advanced Breast Cancer: A Single-Arm, Multicenter Phase II Trial (EPIC Trial). Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s547569

Vancouver

Li R, Wang M, Kong X, Ma J, Qi X, Song Z. Eribulin plus Pyrotinib in Trastuzumab-Resistant, HER2-Positive Advanced Breast Cancer: A Single-Arm, Multicenter Phase II Trial (EPIC Trial). Drug Design, Development and Therapy. 2025. doi:10.2147/dddt.s547569

BibTeX
@article{Li2025,
  author = {Li, Ruoyang and Wang, Meiqi and Kong, Xiangshun and Ma, Jie and Qi, Xiuheng and Song, Zhenchuan},
  title = {Eribulin plus Pyrotinib in Trastuzumab-Resistant, HER2-Positive Advanced Breast Cancer: A Single-Arm, Multicenter Phase II Trial (EPIC Trial)},
  journal = {Drug Design, Development and Therapy},
  year = {2025},
  doi = {10.2147/dddt.s547569}
}
Kostenlos starten →